Mylan Seeks Licensing Partner, Heart Failure Indication For Nebivolol

The company hopes to announce a partner for nebivolol this fall, roughly the same timeframe targeted for discussions with FDA on data needed for a congestive heart failure claim. The beta blocker is “approvable” at FDA for hypertension; Mylan expects to respond to the agency by year-end.